Caisse DE Depot ET Placement DU Quebec lifted its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 1,498.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 328,228 shares of the company’s stock after buying an additional 307,700 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Teva Pharmaceutical Industries were worth $6,220,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of TEVA. Financial Counselors Inc. increased its position in Teva Pharmaceutical Industries by 28.8% during the third quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock worth $3,188,000 after acquiring an additional 40,531 shares during the period. Lockheed Martin Investment Management Co. bought a new position in Teva Pharmaceutical Industries during the third quarter worth $317,000. Stelac Advisory Services LLC bought a new position in Teva Pharmaceutical Industries during the third quarter worth $326,000. Bluestein R H & Co. bought a new position in Teva Pharmaceutical Industries during the third quarter worth $269,000. Finally, New York State Common Retirement Fund increased its position in Teva Pharmaceutical Industries by 14.7% during the third quarter. New York State Common Retirement Fund now owns 780,292 shares of the company’s stock worth $13,733,000 after acquiring an additional 100,200 shares during the period. Institutional investors and hedge funds own 58.20% of the company’s stock.
A number of equities analysts recently issued reports on TEVA shares. BTIG Research boosted their target price on shares of Teva Pharmaceutical Industries to $20.00 in a research report on Friday, December 15th. Goldman Sachs raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday, December 15th. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Citigroup raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Thursday, January 4th. Finally, Mizuho raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and boosted their price target for the company from $19.12 to $23.00 in a report on Tuesday, January 9th. Eleven analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average price target of $20.51.
Shares of NYSE:TEVA traded down $0.32 on Monday, hitting $16.77. The stock had a trading volume of 10,766,180 shares, compared to its average volume of 16,246,001. The company has a market capitalization of $17,378.43, a PE ratio of 4.27, a P/E/G ratio of 1.49 and a beta of 0.67. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86. Teva Pharmaceutical Industries Ltd has a twelve month low of $10.85 and a twelve month high of $33.82.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 EPS. analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.3 EPS for the current year.
In related news, EVP Mark Sabag sold 5,050 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now owns 44,517 shares in the company, valued at approximately $876,094.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 10,734 shares of company stock worth $204,795. 7.10% of the stock is owned by corporate insiders.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.